Results 21 to 30 of about 28,506 (225)

Polymerized Collagen Inhibits Fibroblast Proliferation via a Mechanism Involving the Formation of a β1 Integrin-Protein Phosphatase 2A-Tuberous Sclerosis Complex 2 Complex That Suppresses S6K1 Activity [PDF]

Journal of Biological Chemistry, 2008
Polymerized type I collagen suppresses fibroblast proliferation. Previous studies have implicated inhibition of fibroblast proliferation with polymerized collagen-mediated suppression of S6K1, but the molecular mechanism of the critical negative feedback loop has not yet been fully elucidated. Here, we demonstrate that polymerized collagen suppresses G(
Hong, Xia, Richard, Nho, Jill, Kleidon, Judy, Kahm, Craig A, Henke   +4 more
openaire   +2 more sources

Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2) [PDF]

Biochemical Journal, 2005
The hypertrophic Gq-protein-coupled receptor agonist PE (phenylephrine) activates protein synthesis. We showed previously that activation of protein synthesis by PE requires MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] and mTOR (mammalian target of rapamycin).
Rolfe, M., McLeod, L.E., Pratt, P.F., Proud, C.G.   +3 more
openaire   +3 more sources

Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure [PDF]

Journal of Vascular Surgery, 2013
Chronic renal failure (CRF) is associated with increased cardiovascular mortality, and medial vascular smooth muscle cell (VSMC) hypertrophy, proliferation, and calcification play a pivotal role in uremic vasculopathy. Glucose transporter-1 (GLUT1) facilitates the transport of glucose into VSMCs, and GLUT1 overexpression associated with high glucose ...
Lin, Chih-Yuan, Hsu, Shih-Che, Lee, Herng-Sheng, Lin, Shih-Hua, Tsai, Chien-Sung, Huang, Shih-Ming, Shih, Chun-Che, Hsu, Yu-Juei   +7 more
openaire   +2 more sources

Microglial ASD-related genes are involved in oligodendrocyte differentiation

Scientific Reports, 2021
Autism spectrum disorders (ASD) are associated with mutations of chromodomain-helicase DNA-binding protein 8 (Chd8) and tuberous sclerosis complex 2 (Tsc2).
Yuta Takanezawa, Shogo Tanabe, Daiki Kato, Rie Ozeki, Masayo Komoda, Tatsunori Suzuki, Hiroko Baba, Rieko Muramatsu   +7 more
doaj   +1 more source

ETV2 regulates PARP-1 binding protein to induce ER stress–mediated death in tuberin-deficient cells

Life Science Alliance, 2022
In tuberin-deficient cells, SYK regulates ETV2 nuclear translocation, where it regulated Parpbp expression. Silencing Etv2 or Parpbp induces ER stress–mediated cell death in tuberin-deficient cells.
Shikshya Shrestha, Anthony Lamattina, Gustavo Pacheco-Rodriguez, Julie Ng, Xiaoli Liu, Abhijeet Sonawane, Jewel Imani, Weiliang Qiu, Kosmas Kosmas, Pierce Louis, Anne Hentschel, Wendy K Steagall, Rieko Onishi, Helen Christou, Elizabeth P Henske, Kimberly Glass, Mark A Perrella, Joel Moss, Kelan Tantisira, Souheil El-Chemaly   +19 more
doaj   +1 more source

Cannabinoids in the treatment of epilepsy: current status and future prospects [PDF]

, 2020
Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis sativa, differentiating from Δ9-tetrahydrocannabinol (THC) for its non-intoxicating profile and its antianxiety/antipsychotic effects.
Albini M., Cifelli P., Di Bonaventura C., Fanella M., Giallonardo A. T., Morano A., Palma E.   +6 more
core   +1 more source

mTOR pathway – a potential therapeutic target in stroke

Therapeutic Advances in Neurological Disorders, 2023
Stroke is ranked as the second leading cause of death worldwide and a major cause of long-term disability. A potential therapeutic target that could offer favorable outcomes in stroke is the mammalian target of rapamycin (mTOR) pathway.
Konstantinos Melanis, Maria-Ioanna Stefanou, Konstantinos M. Themistoklis, Themistoklis Papasilekas   +3 more
doaj   +1 more source

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. [PDF]

, 2014
Seizures are clinically significant manifestations associated with 79%-90% of patients with tuberous sclerosis complex. Often occurring within the first year of life in the form of infantile spasms, seizures interfere with neuropsychiatric, social, and ...
Fallah, Aria, Wang, Shelly
core   +2 more sources

Single serine on TSC2 exerts biased control over mTORC1 activation mediated by ERK1/2 but not Akt

Life Science Alliance, 2022
Both ERK1/2 and Akt kinases activate mTORC1, but only the former is bidirectionally regulated by the status of serine S1364 on TSC2 that confers input-selective mTORC1 amplification or attenuation. Tuberous sclerosis complex-2 (TSC2) negatively regulates
Brittany L Dunkerly-Eyring, Shi Pan, Miguel Pinilla-Vera, Desirae McKoy, Sumita Mishra, Maria I Grajeda Martinez, Christian U Oeing, Mark J Ranek, David A Kass   +8 more
doaj   +1 more source

Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex

Human Genomics, 2023
Background Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that is associated with neurological symptoms, including autism spectrum disorder.
Hirofumi Kashii, Shinya Kasai, Atsushi Sato, Yoko Hagino, Yasumasa Nishito, Toshiyuki Kobayashi, Okio Hino, Masashi Mizuguchi, Kazutaka Ikeda   +8 more
doaj   +1 more source